CORDIS · 718711 · H2020
IcoCell Cell line development platform for SMEs to reduce the length and cost of biologic drug development
Coordinator: ICOSAGEN CELL FACTORY OU (EE)
Biologic drugs ($160+ billion market) provide better long-term health outcomes with fewer side effects than many traditional drugs. However, due to high development and production costs, these drugs are 20x more expensive, on average, limiting the access to these therapies and burdening healthcare systems. To a great extent, this is because traditionally flexible and creative biotech SMEs currently lack rational tools for mammalian cell line development (most of the biologic drugs are produced in mammalian cell lines), meaning that large investment in terms of capital and time is required to …
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €1.1M toward a total project budget of €1.6M — a funding rate of 70%, with the remainder covered by the consortium partners. The project runs over approximately 2.3 years from 2016-05-01 to 2018-08-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from EE
see all →- TeamPerMed — CENTRE FOR DATA ENRICHED MEDICINE (TEAMPERMED)101060011 · HORIZON · €15.0M
- FINEST TWINS — Establishment of Smart City Center of Excellence856602 · H2020 · €15.0M
- DIGIBIO — Centre for Digitalisation of Biology Towards the Next-Generation of Biosustainable Products101060066 · HORIZON · €14.9M
- 5G-TIMBER — Secure 5G-Enabled Twin Transition for Europe's TIMBER Industry Sector101058505 · HORIZON · €8.0M
- XSCAVE — Explainable, Safe, Contact-Aware Planning and Control for Heavy Machinery Manipulation and Navigation101189836 · HORIZON · €8.0M
- HEMOS — Holistic heat energy management on ships by implementing innovative dynamic calculation models towards maximum waste heat capture and energy efficiency101056909 · HORIZON · €4.7M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the SME-2 funding scheme.
- What is the EU contribution?
- The European Commission contributes €1.1M toward a total project budget of €1.6M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-SMEInst-2014-2015.
- Who coordinates the project?
- The project is coordinated by ICOSAGEN CELL FACTORY OU (EE).
- What is the project timeline?
- The project runs from 2016-05-01 to 2018-08-31 — approximately 2.3 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 718711.